NCT00577824 - Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Type 2 Diabetes

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg, twice a day

DRUG

exenatide

subcutaneous injection, 10mcg, twice a day

DRUG

placebo

subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day

Trial Locations (12)

Research Site, Chiba

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Kanagawa

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Nagano

Research Site, Osaka

Research Site, Ōita

Research Site, Tokyo